Agile Therapeutics (NASDAQ:AGRX) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Agile Therapeutics (NASDAQ:AGRX) in a research report report published on Friday. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.

Agile Therapeutics Price Performance

Shares of NASDAQ:AGRX opened at $1.51 on Friday. The firm has a fifty day moving average price of $1.48 and a two-hundred day moving average price of $0.91. The company has a market cap of $10.35 million, a price-to-earnings ratio of -0.41 and a beta of 1.58. Agile Therapeutics has a one year low of $0.20 and a one year high of $2.63.

Agile Therapeutics (NASDAQ:AGRX) last posted its earnings results on Monday, August 12th. The specialty pharmaceutical company reported ($0.68) EPS for the quarter. The company had revenue of $5.58 million during the quarter.

Institutional Investors Weigh In On Agile Therapeutics

An institutional investor recently raised its position in Agile Therapeutics stock. Armistice Capital LLC raised its stake in Agile Therapeutics, Inc. (NASDAQ:AGRX) by 10.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 108,000 shares of the specialty pharmaceutical company’s stock after buying an additional 10,000 shares during the period. Armistice Capital LLC owned about 3.65% of Agile Therapeutics worth $211,000 at the end of the most recent quarter. 10.92% of the stock is owned by institutional investors.

About Agile Therapeutics

Agile Therapeutics, Inc, a women's healthcare company, engages in the research, development, and commercialization of prescription contraceptive products for women in the United States. It offers Twirla, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen.